Alzheimer's disease research, amyloid plaques, tau tangles, and cognitive decline
366 articles
A new genetic tracing system reveals the brain's waste-clearance routes are compartmentalized, rapid in some areas, and disrupted differently by inflammation vs. amyloid.
A neuron-specific proteasome system governs tau pathology, with APOE4 carriers showing heightened vulnerability as this system declines with age.
A new Nature Neuroscience study reveals an unexpected molecular mechanism that initiates tau aggregation, the hallmark of Alzheimer's disease.
Researchers at Duke University tested a blood-based biomarker to stratify Alzheimer's patients from healthy adults, aiming to enable earlier detection.
A chromatin-remodeling gene called SMARCAD1 controls tau levels — and switching it off could be a new therapeutic target for Alzheimer's.
A newly identified proteasome activator, PA200, clears toxic alpha-synuclein aggregates and maintains function even when standard protein-disposal systems fail.
A completed Phase 1/2 pilot trial tested whether the senolytic duo D+Q penetrates the brain in early Alzheimer's disease.
A JAMA Insights review breaks down how hearing aids work, their limits, and whether OTC devices stack up against prescription options.
A landmark review reframes astrocytes as multilayered processing units that regulate synapses, circuits, and brain function at multiple spatial scales.
Researchers respond to critiques of their trial showing positive airway pressure therapy may improve cognitive outcomes in Parkinson's disease.
New mouse study reveals why women face higher Alzheimer's risk — local brain estrogen deficiency triggers age-specific memory loss and ECM remodeling.
Microglia package healthy mitochondria into vesicles and deliver them to astrocytes, sharply reducing cognitive decline in tau-pathology mice.
